Amyotrophic Lateral Sclerosis (ALS) Clinical Trial
Official title:
Neuroinflammation in Amyotrophic Lateral Sclerosis - Mechanisms and Therapeutic Perspectives: a Translational Pilot Study Among ALS Patients
Amyotrophic Lateral Sclerosis (ALS) is the most common motor neuron diseases. It is
considered as a rare disease with a prevalence of about 8 per 100,000 persons. Initiating in
mid-life by progressive paralysis, it evolves rapidly into a generalized muscle wasting that
leads irrevocably to death within 2 or 5 years of clinical onset.
Since there is no cure for ALS, the management of the disease is supportive and palliative.
Riluzole is the only drug that has been shown to extend survival by about three months. The
identification of biomarkers sensitive to the progression of the disease might enhance the
diagnostic and provide new drug targets.
Dysfunction of the immune system is a pathological hallmark of ALS. Increased levels of
interferon gamma (IFNgamma) were found in the serum and cerebrospinal fluid (CSF) of ALS
patients. However, the cell origin as well as the pathogenic influence of this peripheral
source of IFNg is unknown. Thus, IFNgamma might have a role in the pathogenic process of ALS
and might be a potential biomarker of the disease.
n/a
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02365922 -
Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)
|
||
| Completed |
NCT01699451 -
DNA, Blood and Skin Cell Repository for Research on ALS and Related Neurodegenerative Disorders at Mayo Clinic Florida
|
||
| Completed |
NCT04577404 -
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 3 | |
| Terminated |
NCT03580616 -
Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Completed |
NCT01884571 -
Immunosuppression in Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Completed |
NCT02118805 -
Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
|
||
| Completed |
NCT00244244 -
A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS
|
Phase 2 | |
| Active, not recruiting |
NCT00420719 -
Motor-Point Stimulation for Conditioning the Diaphragm of Patients With Amyotrophic Lateral Sclerosis (ALS)
|
N/A | |
| Completed |
NCT02936635 -
A Study for Patients Who Completed VITALITY-ALS (CY 4031)
|
Phase 3 | |
| Withdrawn |
NCT04055532 -
Biomarkers in Neurodegenerative Diseases
|
||
| Completed |
NCT03645031 -
Acute Intermittent Hypoxia and Breathing in Neuromuscular Disease
|
N/A | |
| Completed |
NCT01786603 -
Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Completed |
NCT02559869 -
Imaging and BioFluid Biomarkers in Amyotrophic Lateral Sclerosis
|
||
| Completed |
NCT01592552 -
A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
|
||
| Completed |
NCT00403104 -
Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
| Completed |
NCT02017912 -
Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
|
Phase 2 | |
| Completed |
NCT01366027 -
PRISM Registry: Pseudobulbar Affect Registry Series
|
N/A | |
| Completed |
NCT00330681 -
Efficacy and Safety Study of MCI-186 for Treatment of Amyotrophic Lateral Sclerosis (ALS)
|
Phase 3 | |
| Completed |
NCT00876772 -
Olanzapine for the Treatment of Appetite Loss in Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT06351592 -
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
|
Phase 1 |